Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2559)	11/2/2018 6:40:56 PM
From: Miljenko Zuanic	Respond to of 3559

Thanks Tuck. REGN has GITR agonist-Abs from 2016 (provisional application), but there were priority to develop LAG-3, CTLA-4, MUC16,...so a-GITR was secondary target. Glad to see that they are active...finishing line is not determined yet, but yes...MRK/BMY/Roche/Novartis.... do have lead advantage. Anyway, as company that is doing everything on its own,...well, it is not that bad. We do not know how much waste they have in R&D, but science-dedicate employee turnover indicate that they stick with REGN....knowledge is cumulative and stay inside. Now, all we need few more twits from Trump-DUMP,...and things will settle on its own. :-)